Arbor Biotechnologies: An early-stage life sciences company pioneering the next-generation of genetic medicines. With the most extensive library of CRISPR nucleases in the industry, a deep bench of world-class founders, scientific advisors, and a leadership team with a proven track record of developing novel platforms and therapeutics, Arbor is well-positioned to develop curative genetic medicines for all patients with genetic diseases. Arbor’s pipeline is powered by its proprietary biodiscovery engine, which blends computational search and scientific expertise to discover, screen, and engineer proteins at unprecedented scale and speed. Arbor has raised more than $300 million to date and top investors include ARCH Venture Partners, Temasek, Ally Bridge Group, and TCG Crossover. As the Company continues to advance its pipeline toward the clinic with an initial focus in liver and CNS disease, Arbor also secured several partnerships around gene editing and ex vivo cell therapy programs to broaden the reach of its novel nuclease technology.